{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2000"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2004909"],"location":["United States"],"study_start_month":["6"],"keyword":["Recurrent rectal cancer","Recurrent colon cancer","Stage IV rectal cancer","Tipifarnib","Stage IV colon cancer","Adenocarcinoma of the colon","Adenocarcinoma of the rectum"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"S9923 R115777 in Treating Patients With Advanced Colorectal Cancer","description":"RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.\nPURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or advanced colorectal cancer.","dates":{"creation":"2000-06-15"},"accession":"2004909","cross_references":{"ClinicalTrials___gov":["NCT00005833"]}}